Last mentioned: Jul 9, 2026
Across the most recent 4 stories covering SK Biopharmaceuticals — 100% positive sentiment, averaging 7.5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived. See something wrong on this page? Report a data issue.
Collaboration Announced at BIO 2026
Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration, value up to $2.5 billion, to discover AI‑enabled drug candidates for neuroimmune disorders of the CNS.
HKEX-listed Insilico Medicine (3696) projects H1 2026 revenue up 273%–287% to $106.5M, swinging to a net profit of up to $39.5M. The surprise profit alert positions the AI biotech as a high-growth, cash-generating investment.
Source: manilatimes.net · prnewswire.com
A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.
Insilico Medicine's Pharma.AI generative AI platform landed a record $2.5B collaboration with SK Biopharmaceuticals to design and optimize therapeutics for neuroimmune disorders. The deal, announced at BIO 2026, represents the largest validation of an end‑to‑end AI drug discovery engine in the CNS space, proving that generative modeling can transcend oncology and infuse new life into neurology pipelines.
Source: aijourn.com · news-medical.net